Patrick Neven
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (23)
Background: Breast cancer is one of the most common cancers worldwide, with both the disease and the treatments affecting patients’ quality of life and overall survival. Patient preference studies can help to identify what matters most to patients. This study aims to provide an overview of published patient preference studies in breast cancer, focusing on (i) the design of the study, (ii) preference outcomes including preference heterogeneity, (iii) recruitment strategies, and (iv) patient involvement. Methods: For this scoping review, a search strategy was created for five databases (PubMed, Embase, Scopus, Web of Science Core Collection, and CINAHL), based on the concepts ‘breast cancer’ and ‘patient preference’. The articles were screened double-blind in two phases, after which, the relevant data was extracted and analyzed. Results: A total of 31 articles were selected based on the eligibility criteria. The studies were published over a wide time range (1995–2024), and across different countries. Different methodologies were used, and different attributes were included, mainly related to adverse events of treatments and survival elements. Survival elements were almost always considered important when included. Preference heterogeneity was assessed in 24 of the included studies. The involvement of patients in these studies varied; in two studies, patients were involved in an advisory board; in five studies, patients provided feedback on the preference study conduct via interviews or focus group discussions; and in twelve studies, pilot tests were mentioned. Conclusions: The studies show diverse methods, outcomes, and patient involvement strategies. This may complicate the implementation of preferences in decision-making, suggesting preference studies with clear objectives and implementation strategies to create impact for and with patients.
Year:
2025
Purpose: Patients with postpartum breast cancer diagnosed after cessation of breastfeeding (postweaning, PP-BC PW ) have a particularly poor prognosis compared with patients diagnosed during lactation (PP-BC DL ), or to pregnant (Pr-BC) and nulliparous (NP-BC) patients, regardless of standard prognostic characteristics. Animal studies point to a role of the involution process in stimulation of tumor growth in the mammary gland. However, in women, the molecular mechanisms that underlie this poor prognosis of patients with PP-BC PW remain vastly underexplored, due to of lack of adequate patient numbers and outcome data. Experimental Design: We explored whether distinct prognostic features, common to all breast cancer molecular subtypes, exist in postpartum tumor tissue. Using detailed breastfeeding data, we delineated the postweaning period in PP-BC as a surrogate for mammary gland involution and performed whole transcriptome sequencing, immunohistochemical, and (multiplex) immunofluorescent analyses on tumor tissue of patients with PP-BC PW , PP-BC DL , Pr-BC, and NP-BC. Results: We found that patients with PP-BC PW having a low expression level of an immunoglobulin gene signature, but high infiltration of plasma B cells, have an increased risk for metastasis and death. Although PP-BC PW tumor tissue was also characterized by an increase in CD8 + cytotoxic T cells and reduced distance among these cell types, these parameters were not associated with differential clinical outcomes among groups. Conclusions: These data point to the importance of plasma B cells in the postweaning mammary tumor microenvironment regarding the poor prognosis of PP-BC PW patients. Future prospective and in-depth research needs to further explore the role of B-cell immunobiology in this specific group of young patients with breast cancer.
Year:
2025
Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study. Patients and Methods: Postmenopausal women with untreated, operable estrogen receptor (ER)–positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed. Results: Among evaluable paired samples ( n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose. Conclusions: EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.
Year:
2024
Purpose: Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER + ), HER2 − metastatic breast cancer and tumors harboring estrogen receptor 1 ( ESR1 ) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i). In patients with ESR1 -mutated tumors, we evaluated the efficacy and safety of elacestrant versus SOC based on prior ET+CDK4/6i duration and in clinical subgroups with prior ET+CDK4/6i ≥12 months. Patients and Methods: EMERALD, an open-label phase III trial, randomly assigned patients with ER + , HER2 − metastatic breast cancer who had received 1–2 prior lines of ET, mandatory CDK4/6i, and ≤1 chemotherapy to elacestrant (345 mg daily) or SOC (aromatase inhibitor or fulvestrant). PFS was assessed across subgroups in post hoc exploratory analyses without adjustment for multiple testing. Results: In patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63). In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases), 9.0 versus 1.9 ( PIK3 catalytic subunit α mutation), 8.6 versus 1.9 (tumor protein p53 gene mutation), 9.0 versus 1.9 (HER2-low), 9.0 versus 1.9 ( ESR1 D538G -mutated tumors), and 9.0 versus 1.9 ( ESR1 Y537S/N -mutated tumors). Subgroup safety was consistent with the overall population. Conclusions: The duration of prior ET+CDK4/6i ≥12 months in metastatic breast cancer was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC and was consistent across all subgroups evaluated in patients with ER + , HER2 − , ESR1 -mutated tumors.
Year:
2024
PFS according to mutation and molecular expression subgroups. Kaplan–Meier estimates of PFS in patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months who, at screening, had the presence of ( A ) PIK3CA -mut ( n = 62; 39%); ( B ) PIK3CA wild-type ( n = 97; 61%); ( C ) TP53 -mut ( n = 61; 38%); ( D ) TP53 wild-type ( n = 97; 61%); ( E ) HER2-low expression ( n = 77; 48%); ( F ) HER2-zero expression ( n = 69; 43%); ( G ) ESR1 D538G -mutated tumors ( n = 97; 61%); or ( H ) ESR1 Y537S/N -mutated tumors ( n = 92; 58%). a Includes the following PIK3CA -mut: E545K, H1047R, and E542K among others. b Data not available for all patients. c HER2-low expression defined as IHC score of 1+ or 2+ with no amplification by ISH.
Year:
2024
PFS in patients who received prior ET+CDK4/6i ≥12 months in the metastatic setting. Kaplan–Meier estimates of PFS in patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months in the metastatic setting ( n = 159).
Year:
2024
PFS according to clinical subgroups. Kaplan–Meier estimates of PFS in patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months who, at screening, had the presence of ( A ) bone metastases ( n = 136; 86%); ( B ) liver and/or lung metastases ( n = 113; 71%); ( C ) n = 82; 52%); or ( D ) ≥3 metastatic sites ( n = 53; 33%). a Eighty-five percent of patients had bone and other sites of metastases (30% of these patients had no liver or lung involvement). b Fifty-five percent of patients had liver and other sites of metastases (10% of these patients had no lung or bone involvement); 25% of patients had lung and other sites of metastases (2% of these patients had no liver or bone involvement). c The number of metastatic sites was available for 135 of 159 patients with ESR1 -mutated tumors and prior ET+CDK4/6i ≥12 months.
Year:
2024
Purpose: Postpartum breast cancer patients diagnosed after cessation of breastfeeding (post-weaning, PP-BC PW ), have a particularly poor prognosis compared to patients diagnosed during lactation (PP-BC DL ), or to pregnant (Pr-BC) and nulliparous (NP-BC) patients, irrespective of standard prognostic characteristics. Animal studies point to a role of the involution process in stimulation of tumor growth in the mammary gland. However, in women, the molecular mechanisms that underlie this poor prognosis of PP-BC PW patients remain vastly underexplored, due to of lack of adequate patient numbers and outcome data. Experimental Design: We explored whether distinct prognostic features, common to all breast cancer molecular subtypes, exist in postpartum tumor tissue. Using detailed breastfeeding data, we delineated the post-weaning period in PP-BC as a surrogate for mammary gland involution and performed whole transcriptome sequencing, immunohistochemical and (multiplex) immunofluorescent analyses on tumor tissue of PP-BC PW , PP-BC DL , Pr-BC and NP-BC patients. Results: We found that PP-BC PW patients having a low expression level of an immunoglobulin gene signature, but high infiltration of plasma B-cells, have an increased risk for metastasis and death. Although PP-BC PW tumor tissue was also characterized by an increase in CD8+ cytotoxic T-cells and reduced distance among these cell types, these parameters were not associated with differential clinical outcomes among groups. Conclusion: These data point to the importance of plasma B-cells in the post-weaning mammary tumor microenvironment regarding the poor prognosis of PP-BC PW patients. Future prospective and in-depth research needs to further explore the role of B-cell immunobiology in this specific group of young breast cancer patients.
Year:
2024
Purpose: Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i). In patients with ESR1-mutated tumors, we evaluated the efficacy and safety of elacestrant versus SOC based on prior ET+CDK4/6i duration and in clinical subgroups with prior ET+CDK4/6i ≥12 months. Patients and Methods: EMERALD, an open-label phase III trial, randomly assigned patients with ER+, HER2− metastatic breast cancer who had received 1–2 prior lines of ET, mandatory CDK4/6i, and ≤1 chemotherapy to elacestrant (345 mg daily) or SOC (aromatase inhibitor or fulvestrant). PFS was assessed across subgroups in post hoc exploratory analyses without adjustment for multiple testing. Results: In patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63). In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases), 9.0 versus 1.9 (<3 metastatic sites), 10.8 versus 1.8 (≥3 metastatic sites), 5.5 versus 1.9 (PIK3 catalytic subunit α mutation), 8.6 versus 1.9 (tumor protein p53 gene mutation), 9.0 versus 1.9 (HER2-low), 9.0 versus 1.9 (ESR1D538G-mutated tumors), and 9.0 versus 1.9 (ESR1Y537S/N-mutated tumors). Subgroup safety was consistent with the overall population. Conclusions: The duration of prior ET+CDK4/6i ≥12 months in metastatic breast cancer was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC and was consistent across all subgroups evaluated in patients with ER+, HER2−, ESR1-mutated tumors.
Year:
2024
PURPOSE AMEERA-5 investigated amcenestrant (oral selective estrogen receptor [ER] degrader) plus palbociclib versus letrozole plus palbociclib as first-line treatment for ER-positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced/metastatic breast cancer (aBC). MATERIALS AND METHODS In AMEERA-5 (ClinicalTrials.gov identifier: NCT04478266 ), a double-blind, double-dummy, international phase III trial, adult pre-/post-menopausal women and men without previous systemic therapy for ER+/HER2– aBC were randomly assigned 1:1 to amcenestrant 200 mg once daily + standard palbociclib dosage (125 mg once daily, 21 days on/7 days off) or letrozole 2.5 mg once daily + standard palbociclib dosage, stratified by de novo metastatic disease, postmenopausal women, and visceral metastasis. The primary end point was progression-free survival (PFS), compared using a stratified log-rank test with one-sided type I error rate of 2.5%. Secondary end points included overall survival (key secondary), pharmacokinetics, and safety. RESULTS Between October 14, 2020, and December 2, 2021, 1,068 patients were randomly assigned to amcenestrant + palbociclib (N = 534) or letrozole + palbociclib (N = 534). At the interim analysis (median follow-up 8.4 months), the stratified hazard ratio for PFS was 1.209 (95% CI, 0.939 to 1.557; one-sided P value = .9304); therefore, the study was stopped for futility. The 6-month PFS rate was 82.7% (95% CI, 79.0 to 85.8) with amcenestrant + palbociclib versus 86.9% (95% CI, 83.5 to 89.6) with letrozole + palbociclib. In the amcenestrant + palbociclib versus letrozole + palbociclib groups, treatment-emergent adverse events (any grade) occurred in 85.6% versus 85.4% of patients and grade ≥3 events in 46.3% versus 60.8%, respectively. CONCLUSION The AMEERA-5 study was discontinued on the basis of the recommendation of the data monitoring committee at the interim futility analysis. No new safety signals were identified.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (30)
Anne Vincent‐Salomon
Professor (associate)
Université Paris Dauphine-PSL
Katarzyna Joanna Jerzak
University of Toronto
Joyce O'Shaughnessy
Baylor University Medical Center
François Bertucci
Professor
Institut Paoli-Calmettes
Lodewyk Wessels
Professor
Delft University of Technology
Christine Desmedt
Head of Laboratory for Translational Breast Cancer Research
KU Leuven
Kristel Van Calsteren
KU Leuven
Diether Lambrechts
Science Director
KU Leuven
Francois-Clement Bidard
Professor of Medical Oncology
Institut Curie
Nadia Harbeck
-
Hope Rugo
Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology
City Of Hope National Medical Center
Kelly K Hunt
Chair
The University of Texas MD Anderson Cancer Center
Peter Schmid
Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine
Barts Cancer Institute
Federica Grillo
Assistant Professor
University of Genoa
Matteo Lambertini
University of Genova
Peter Fasching
-
Swati Kulkarni
Professor of Surgery
Northwestern University
Frédéric Amant
Antoni van Leeuwenhoek Nederlands Kanker Instituut
Ellen Warner
University of Toronto
Sara Hurvitz
Professor, Division Head
Washington University School of Medicine
Elia Mario Biganzoli
Full Professor Medical Statistics
University of Milan
Virginia Kaklamani
Professor
University of Texas Health Science Center at San Antonio
Aditya Bardia
UCLA Health
Charlotte Maggen
Vrije Universiteit Brussel
Miguel Martin
Universidad Complutense de Madrid
Gabriele Zoppoli
University of Genoa
Manali Bhave
Assistant Professor
Winship Cancer Institute of Emory University
Sophia Leduc
Vrije Universiteit Brussel
Eva M. Ciruelos-Gil
Universidad Complutense de Madrid
Fedro Peccatori
Director, Fertility nd Procreation in Oncology Unit
European Institute of Oncology
Make your next move.
Prepare your application
Review drafts before you send them.